AN2 Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$38.1M | -$56.8M | -$69.6M | -$42.3M | -$21.6M |
| Operating expenses | $38.1M | $56.8M | $69.6M | $42.3M | $21.6M |
| Cash from operations | -$29.8M | -$49.3M | -$53.3M | -$33.5M | -$20.5M |
| Total assets | $62.0M | $92.1M | $138.7M | $102.6M | $65.3M |
| Total liabilities | $8.9M | $10.2M | $14.0M | $7.2M | $3.4M |
Shares outstanding 36.0M · Free float 66.3%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.